Although biomarkers of immunotherapy in glioblastoma have been widely studied, there are few biomarkers that can predict the therapeutic efficacy of glioblastoma treated with PD‐1/PD‐L1 blockade. This evidence concerns the gene CD274 and glioblastoma.